Atterocor names new CMO
This article was originally published in Scrip
Atterocor, a company developing drugs for adrenal cancer, has named Dr Pharis Mohideen chief medical officer. He will lead all clinical strategies and activities, including overseeing the development of ATR-101, the company's investigational therapy for the treatment of adrenocortical carcinoma (ACC). Prior to joining Ann Arbor, Michigan-based Atterocor, Dr Mohideen was vice-president of clinical development at Shionogi.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.